We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+4.86%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$8.07B
AUM Growth
+$160M
Cap. Flow
-$9.82B
Cap. Flow %
-121.72%
Top 10 Hldgs %
33.87%
Holding
157
New
25
Increased
29
Reduced
33
Closed
16

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$192M
2
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$173M
3
MRK icon
Merck
MRK
+$94.1M
4
THC icon
Tenet Healthcare
THC
+$83.4M
5
DVA icon
DaVita
DVA
+$79.5M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$9.91B
2
LLY icon
Eli Lilly
LLY
+$193M
3
AMGN icon
Amgen
AMGN
+$156M
4
CI icon
Cigna
CI
+$151M
5
ELV icon
Elevance Health
ELV
+$148M

Sector Composition

Rank Sector Weight
1 Healthcare 98%
2 Miscellaneous 1.49%
3 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABT icon
76
Abbott
ABT
$176B
$23.6M 0.29%
+394,100
New +$23.7M
NTLA icon
77
Intellia Therapeutics
NTLA
$1.66B
$23.5M 0.29%
1,113,000
-1,224,684
-52% -$30.1M
INSY
78
DELISTED
Insys Therapeutics, Inc.
INSY
$21.2M 0.26%
3,511,544
-1,895,300
-35% -$15.6M
MD icon
79
Pediatrix Medical
MD
$2.18B
$20.6M 0.26%
+370,000
New +$20.3M
NBRV
80
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$19.7M 0.24%
15,678
– –
CTIC
81
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$19.5M 0.24%
5,000,000
– –
SYBX
82
DELISTED
Synlogic
SYBX
$19M 0.24%
135,333
+47,667
+54% +$7.39M
RNAC icon
83
Cartesian Therapeutics
RNAC
$248M
$18.8M 0.23%
61,427
– –
XNCR icon
84
Xencor
XNCR
$1.81B
$18.4M 0.23%
612,500
-409,600
-40% -$10.7M
NVO
85
Novo Nordisk
NVO
$192B
$16.3M 0.2%
660,000
– –
CHRS icon
86
Coherus Oncology
CHRS
$205M
$16.2M 0.2%
1,466,800
-4,700
-0.3% -$51.4K
KTWO
87
DELISTED
K2M Group Holdings, Inc
KTWO
$16M 0.2%
+843,205
New +$16.7M
IMGN
88
DELISTED
Immunogen Inc
IMGN
$15.8M 0.2%
1,504,270
-1,329,856
-47% -$13.1M
GTS
89
DELISTED
Triple-S Management Corporation
GTS
$14.8M 0.18%
+594,927
New +$14.2M
NTRA icon
90
Natera
NTRA
$47.4B
$14.6M 0.18%
1,576,190
– –
SYRE icon
91
Spyre Therapeutics
SYRE
$7.99B
$14.6M 0.18%
58,781
– –
RCKT icon
92
Rocket Pharmaceuticals
RCKT
$368M
$14.5M 0.18%
+775,000
New +$12.6M
ZLAB icon
93
Zai Lab
ZLAB
$2.71B
$14.1M 0.17%
658,160
– –
STDY
94
DELISTED
SteadyMed Ltd
STDY
$13.8M 0.17%
4,246,196
– –
ELDN icon
95
Eledon Pharmaceuticals
ELDN
$226M
$12.8M 0.16%
140,951
– –
BMY icon
96
CALL
Bristol-Myers Squibb
BMY
$130B
$12.7M 0.16%
+200,000
New +$12.9M
AMED
97
DELISTED
Amedisys
AMED
$12.5M 0.16%
207,500
– –
WMGIZ
98
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
$12M 0.15%
8,746,583
– –
BMRN icon
99
BioMarin Pharmaceuticals
BMRN
$12.7B
$11.8M 0.15%
145,500
+44,900
+45% +$3.85M
XRAY icon
100
Dentsply Sirona
XRAY
$2.09B
$11.3M 0.14%
+225,000
New +$13.2M
2 3
4
5 6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2018 Portfolio in Review

As of Q1 2018, OrbiMed held 157 positions worth $8.07B, up 2% from $7.91B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed withdrew a net $9.82B in Q1 2018, closing 16 positions and reducing 33 holdings. Its most notable exit was Eli Lilly, an estimated $193M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, OrbiMed opened a new position in ARMO BioSciences, Inc. Common Stock worth $154M.

  • OrbiMed's largest Q1 2018 buy was ARMO BioSciences, Inc. Common Stock: 4,118,903 shares worth $154M.
  • OrbiMed added most to Bristol-Myers Squibb in Q1 2018, an estimated $192M increase.
  • OrbiMed's biggest Q1 2018 reduction was Loxo Oncology, Inc, cutting an estimated $9.91B.
  • OrbiMed fully exited Eli Lilly in Q1 2018, selling an estimated $193M.
  • OrbiMed's ten largest holdings make up 34% of its $8.07B portfolio in Q1 2018.
  • OrbiMed opened 25 new positions and closed 16 in Q1 2018.
  • OrbiMed's portfolio value rose 2% quarter-over-quarter to $8.07B.

Based on OrbiMed's 13F filing for Q1 2018, filed 15 May 2018.